PORTLAND, Ore. — Paragon BioTeck, Inc., today announced that it has signed a distribution agreement with Horus Pharma for rights to supply the ilast® range of its medical-grade ocular hygiene and lid care products within the United States; it begins on an exclusive basis this month.
“This agreement with Horus Pharma demonstrates Paragon’s commitment to partnering with companies that are dedicated to elevating eye care in the U.S.,” Patrick Witham, president and CEO of Paragon BioTeck, says. “It is also an example of Paragon’s ongoing commitment to further develop and foster an unparalleled network of collaborative partners.”
Martine Claret, president of Horus Pharma, is also excited about the partnership.
“Our partnership with Paragon is a significant milestone in our company’s global commercialization efforts,” she says. “ilast® is an important advancement in eye care because it is the only preservative, fragrance and alcohol-free line of ocular hygiene and lid care products available in the U.S.”
Preservative-free and containing a high concentration of hyaluronic acid, ilast® is scientifically-formulated and uses the unique, patented-manufacturing process – Epifree® Technology. The proprietary process of low-temperature sterilization allows the product to maintain its microbiological integrity while maximizing the quality of active ingredients and ensuring a high level of efficacy. Epifree® Technology was designed to eliminate a wide range of cytotoxic and allergenic properties due to the preservatives that may cause irritation or contribute to certain pre-existing conditions affecting the eye and delicate skin surrounding the eye.
About Horus Pharma
French Innovation Lab, Horus Pharma, is a leading pioneer in France and throughout Europe, and offers a first-in-class, medical-grade range of preservative-free ocular hygiene and lid care products containing a high concentration of hyaluronic acid, featuring the company’s patented Epifree® Technology.
About Paragon BioTeck, Inc.
Paragon BioTeck, Inc., is a privately-held, ophthalmic-focused biopharmaceutical and medical device company pursuing the development and commercialization of products addressing unmet medical needs in the fight to protect and preserve eyesight.